Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Cwm LLC

Cwm LLC lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 66.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,512 shares of the biopharmaceutical company's stock after selling 11,152 shares during the quarter. Cwm LLC's holdings in Alnylam Pharmaceuticals were worth $1,797,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Bayforest Capital Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company's stock worth $83,000 after purchasing an additional 39 shares during the period. Fulton Bank N.A. grew its holdings in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company's stock worth $463,000 after purchasing an additional 46 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Alnylam Pharmaceuticals by 10.3% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company's stock worth $142,000 after purchasing an additional 49 shares during the period. Edmond DE Rothschild Holding S.A. grew its holdings in shares of Alnylam Pharmaceuticals by 18.2% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 49 shares during the period. Finally, Lindbrook Capital LLC grew its holdings in shares of Alnylam Pharmaceuticals by 9.2% during the 1st quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock worth $161,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Scotiabank boosted their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a report on Friday, August 1st. Stifel Nicolaus upped their price target on Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a "buy" rating in a report on Monday, October 6th. Chardan Capital upped their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Oppenheimer upgraded Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price for the company in a research note on Monday, August 4th. Finally, Raymond James Financial assumed coverage on Alnylam Pharmaceuticals in a research note on Wednesday, July 30th. They set an "outperform" rating and a $370.00 target price for the company. Twenty-four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $463.08.

Alnylam Pharmaceuticals Trading Up 0.1%

Shares of ALNY stock opened at $481.67 on Monday. The stock has a 50-day simple moving average of $455.90 and a 200 day simple moving average of $353.43. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $492.62. The stock has a market capitalization of $63.14 billion, a P/E ratio of -195.01 and a beta of 0.36. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same quarter last year, the company posted ($0.13) EPS. Alnylam Pharmaceuticals's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president directly owned 54,052 shares of the company's stock, valued at approximately $24,434,206.60. This represents a 6.60% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares of the company's stock, valued at approximately $11,405,673.55. This represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 98,144 shares of company stock worth $44,160,261. 1.20% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.